TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05075681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide
Description: Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide.~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;
Study: NCT04574960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2, IV infusion on days 1 and 8 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2, IV infusion on days 1 and 8 of each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 70 mg/m\^2, IV infusion on day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m\^2, IV infusion on day 1 of each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle
Study: NCT06740630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Description: MMR vaccine co-administered subcutaneously or intramuscularly.
Study: NCT06627452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Neuromuscular Stabilization Training
Description: Patients will be taught how to perform exercises in different developmental positions both manually and verbally by the DNS therapist. In the DNS concept, proper breathing patterns are important alongside stabilization, and elastic bands will be used to regulate intra-abdominal pressure (IAP) and teach correct breathing. The elastic band will be secured around the chest just below the ribcage, and the patient will be asked to expand the elastic band in all directions while inhaling, thereby regulating the IAP. After teaching IAP guidance, exercises will be conducted in developmental positions with IAP regulation. The exercises will be conducted twice a week under the supervision of a physiotherapist, and three days at home, with sessions lasting approximately 30 minutes, for a total of five days a week over a period of 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training
Description: Pelvic floor exercises involving both slow and fast muscle contractions will be taught to patients through vaginal palpation. During fast contractions, patients will be instructed to quickly contract and relax their pelvic floor muscles. During slow contractions, patients will be asked to gradually squeeze their pelvic floor muscles, hold for 10 seconds, and then slowly relax. Each set of pelvic floor exercises will consist of 10 fast contractions and 10 slow contractions. Patients will perform pelvic floor exercises twice a week with a physiotherapist and three days at home. The exercises will be done in sets throughout the day, lasting approximately 30 minutes, and will be conducted over a period of 12 weeks.
Study: NCT06319495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation therapy
Description: During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT06740630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Description: MMR vaccine co-administered subcutaneously or intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Description: MMR vaccine co-administered subcutaneously or intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR vaccine
Description: MMR vaccine co-administered subcutaneously or intramuscularly.
Study: NCT06319495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: 1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT04629963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Evaluation and BPISF
Description: Current diagnostic approaches guide evaluators to use the United Nations Istanbul Protocol (UNIP) for the assessment of torture survivors. The proposed investigation offers a novel diagnostic paradigm by which participants are evaluated by the UNIP and a validated pain screen (Brief Pain Inventory Short Form).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys, a fingerstick blood sample, EMAs, and a digital wearable device
Description: The following surveys: BPI-SF, RHS-15, RTHC, SOIS-SF, RPMS, WHOAQ, QVSFS, a fingerstick blood sample, EMAs, and a digital wearable device
Study: NCT06627062

Intervention type: PROCEDURE
Intervention: moderate and severe subluxated lens extraction
Description: A double-strand polypropylene suture (9-0 or 8-0) was looped and tied to one end of the preloaded CTR, which was then implanted into the capsular bag. The needle was inserted through the main incision, traversed the anterior chamber, under the posterior iris, and exited 2.0 mm behind the limbus at the central zonular weakness. The CTR was secured to the sclera using the knotless Z-suture technique to center the capsular bag, allowing safe insertion of the intraocular lens (IOL).
Study: NCT06705465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video conference
Description: video conference
Study: NCT06720584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coach-led, online support program for people living with lupus
Description: The health coach-led online support and education program for people living with lupus. It includes 8 group sessions and 2 individual sessions with the health coach to set individual goals. Each program group will include up to 10 participants.~Program Session Structure (\~60-75 minutes): educational component presented using a slide set, discussion questions interspersed, mindfulness activities, goal check-ins.~Associated Materials: Notebook, expert videos available.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health coach-led, online support program for people living with lupus
Description: The health coach-led online support and education program for people living with lupus. It includes 8 group sessions and 2 individual sessions with the health coach to set individual goals. Each program group will include up to 10 participants.~Program Session Structure (\~60-75 minutes): educational component presented using a slide set, discussion questions interspersed, mindfulness activities, goal check-ins.~Associated Materials: Notebook, expert videos available.
Study: NCT06741696

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical extraction
Description: saline irrigation at different temperatures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical extraction
Description: saline irrigation at different temperatures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: saline irrigations
Description: saline irrigation done after 3rd molar surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: saline irrigations
Description: saline irrigation done after 3rd molar surgery
Study: NCT06736990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAL101
Description: Intravenous infusions of CAL101 every 4 weeks over 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusions of placebo every 4 weeks over 24 weeks
Study: NCT06741397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Injections administered IM gluteal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New formulation of CAB LA
Description: Injections administered IM gluteal.
Study: NCT06743412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular music listening
Description: Regular listening of self-selected music sung in Italian language during the hospital stay and after discharge till the follow-up visit after 3 months.
Study: NCT05460507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retreatment Rhenium Liposome
Description: At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
Study: NCT06741748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Warming Method
Description: This intervention involves thawing vitrified blastocysts using a simplified, one-step direct warming method. The blastocyst is placed in a pre-warmed embryo culture medium for approximately one minute, then transferred directly into the embryo culture medium within a time-lapse system until ready for uterine transfer. The total thawing process takes approximately three minutes, reducing the duration and complexity of the procedure compared to conventional methods.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Multi-step Thawing Method
Description: This intervention involves thawing vitrified blastocysts using a standard, multi-step process. The procedure includes sequential exposure of the blastocyst to different thawing solutions containing varying concentrations of cryoprotectants, followed by its transfer into an embryo culture medium in a time-lapse system. The overall process takes approximately 10-30 minutes.
Study: NCT06742918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was given to the Group IV which was 2 grams of glucose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given to the Group IV which was 2 grams of glucose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo was given to the Group IV which was 2 grams of glucose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was given to the Group IV which was 2 grams of glucose.
Study: NCT06741371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monocryl
Description: Closure of the uterine scar by monofilament suture material
Study: NCT06743282

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Subjects will have monthly check-in meetings with the Integrated Behavioral Healthcare manager, complete monthly urine tests for substance use, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete baseline questionnaires.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Senyo App
Description: Subjects will engage with the Senyo Health platform for 12 weeks to deliver Integrated Behavioral Healthcare (IBH) treatment. The Senyo Health platform consists of asynchronous cognitive behavioral therapy modules and weekly check-ins with the IBH care manager. Subjects will also complete a monthly urine test for substances, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete weekly questionnaires.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Senyo App
Description: Subjects will engage with the Senyo Health platform for 12 weeks to deliver Integrated Behavioral Healthcare (IBH) treatment. The Senyo Health platform consists of asynchronous cognitive behavioral therapy modules and weekly check-ins with the IBH care manager. Subjects will also complete a monthly urine test for substances, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete weekly questionnaires.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: Subjects will have monthly check-in meetings with the Integrated Behavioral Healthcare manager, complete monthly urine tests for substance use, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete monthly questionnaires.
Study: NCT06741644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS2009
Description: CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS2009
Description: CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).
Study: NCT04247243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid testing
Description: Abbott ID NOW Strep A testing

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reference testing
Description: Culture-based testing
Study: NCT04847466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every 4 weeks (1 week after starting treatment with the PDL-1 CAR-NK cells).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg will be administered as a 30-minute IV infusion every 6 weeks. Pembrolizumab will be administered on the same day as the PD-L1 CAR-NK cells.
Study: NCT05804162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide Placebo
Description: Participants will receive cagrilintide placebo subcutaneously once weekly.
Study: NCT04847466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: PD-L1 CAR NK cells (2x109) will be administered by IV infusion over approximately 30 minutes every week. After the week 6 treatment, these cells will be given every 2 weeks.
Study: NCT05804162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide Placebo
Description: Participants will receive cagrilintide placebo subcutaneously once weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Partcipants will receive a single dose of moxifloxacin orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Partcipants will receive a single dose of moxifloxacin orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Partcipants will receive a single dose of moxifloxacin orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Partcipants will receive a single dose of moxifloxacin orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Partcipants will receive a single dose of moxifloxacin orally.
Study: NCT06364748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellular enabled blood pressure cuff
Description: Smart cuff

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Cuff
Description: Standard blood pressure cuff
Study: NCT05170737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEF0217
Description: PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEF0217
Description: PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEF0217
Description: PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD.
Study: NCT06138873

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular tachycardia ablation with no AI-guidance
Description: As described in arms descriptions
Study: NCT05615688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pain Intensity following Placement of Orthodontic Separators
Description: Elastomeric separators will be placed on the mesial and distal of lower first permanent molars for a total of four separators per subject. Subjects will wear receive an activity monitor prior to placement of elastic separators and instructed to wear it 24/7 unless showering or swimming. Subjects will complete a recurrent Pain Scale Questionnaire 2-4 hrs after placement of elastics and every 24 hrs from day 2- 7.
Study: NCT06236451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole will be started at dose of 10 mg/day and increased to a stable dose of 20 mg/day over 2-3 weeks and will be continued till 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone will be started at dose of 2 mg/day and increased to a stable dose of 6 mg/day over 2-3 weeks and continued till 12 weeks.
Study: NCT06434064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy